For instance, increased Blimp-1 activity in Tregs and Th17 cells might significantly reduce joint inflammation and oxidative damage in inflammatory bowel disease and improve patient outcomes [8,9]. This evidence concerns the gene PRDM1 and inflammatory bowel disease.